-
EP3842529
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3842529
| EP3842529 - EXOSOME-BASED ANTITUMOR VACCINE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 28.05.2021 Database last updated on 31.05.2024 | |
| Former | The international publication has been made Status updated on 28.02.2020 | Most recent event Tooltip | 18.08.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Institute Of Process Engineering Chinese Acadamy Of Sciences 1 North 2nd Street Zhongguancun Haidian District 100190 Beijing / CN | [2021/26] | Inventor(s) | 01 /
MA, Guanghui 1 North 2nd Street, Zhongguancun Haidian District Beijing 100190 / CN | 02 /
WEI, Wei 1 North 2nd Street Zhongguancun Haidian District Beijing 100190 / CN | 03 /
WANG, Shuang 1 North 2nd Street, Zhongguancun Haidian District Beijing 100190 / CN | 04 /
QING, Shuang 1 North 2nd Street, Zhongguancun Haidian District Beijing 100190 / CN | 05 /
WANG, Jianghua 1 North 2nd Street, Zhongguancun Haidian District Beijing 100190 / CN | [2021/26] | Representative(s) | Niu, Lijiang Hochalmstraße 5 81825 München / DE | [2021/26] | Application number, filing date | 19852773.1 | 16.08.2019 | [2021/26] | WO2019CN101079 | Priority number, date | CN201810946746 | 20.08.2018 Original published format: CN201810946746 | [2021/26] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020038299 | Date: | 27.02.2020 | Language: | ZH | [2020/09] | Type: | A1 Application with search report | No.: | EP3842529 | Date: | 30.06.2021 | Language: | EN | [2021/26] | Search report(s) | International search report - published on: | CN | 27.02.2020 | (Supplementary) European search report - dispatched on: | EP | 13.05.2022 | Classification | IPC: | C12N5/22, A61K45/00, A61P35/00, A61K35/13, A61K35/15, A61K35/17, A61K39/00, A61K45/06, C12N5/0786, C12N5/10 | [2022/24] | CPC: |
A61K45/06 (EP);
C12N5/16 (CN);
C12N5/163 (CN,US);
A61K35/13 (EP);
A61K35/15 (EP,CN);
A61K35/17 (EP,CN);
A61K39/0011 (EP,CN,US);
A61P35/00 (EP,CN,US);
C07K16/2818 (US);
C07K16/2827 (US);
C12N5/0645 (EP,CN);
C12N5/10 (EP);
| C-Set: |
A61K35/13, A61K2300/00 (EP);
A61K35/15, A61K2300/00 (EP,CN);
A61K35/17, A61K2300/00 (CN,EP)
|
| Former IPC [2021/26] | C12N5/22, A61K45/00, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/26] | Title | German: | ANTITUMORVAKZINE AUF EXOSOMBASIS | [2021/26] | English: | EXOSOME-BASED ANTITUMOR VACCINE | [2021/26] | French: | VACCIN ANTI-TUMORAL À BASE D'EXOSOMES | [2021/26] | Entry into regional phase | 05.03.2021 | Translation filed | 18.03.2021 | National basic fee paid | 18.03.2021 | Search fee paid | 18.03.2021 | Designation fee(s) paid | 19.03.2021 | Examination fee paid | Examination procedure | 19.03.2021 | Examination requested [2021/26] | 15.11.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 18.03.2021 | Renewal fee patent year 03 | 05.08.2022 | Renewal fee patent year 04 | 18.08.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X] - MINGYE FENG ET AL, "Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20150217), vol. 112, no. 7, doi:10.1073/pnas.1424907112, ISSN 0027-8424, pages 2145 - 2150, XP055470309 [X] 1,2,8,9,11,12 * abstract * * Also discussion, starting page 2148, col. 1 until page 2149 col. 1 first sentence.; page 2145, column 2, paragraph 2 - page 2146, column 2, paragraph 1 * DOI: http://dx.doi.org/10.1073/pnas.1424907112 | [X] - ZHUANG CHEN ET AL, "Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, (20010522), vol. 93, no. 4, doi:10.1002/IJC.1365, ISSN 0020-7136, pages 539 - 548, XP071280103 [X] 1,8,9,11,12 * abstract * * page 546, column 1, paragraph 2 * * page 547, column 1, paragraph 2 - column 2, paragraph 2 * DOI: http://dx.doi.org/10.1002/ijc.1365 | [X] - SHIGEO KOIDO, "Dendritic-Tumor Fusion Cell-Based Cancer Vaccines", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, (20160526), vol. 17, no. 6, doi:10.3390/ijms17060828, page 828, XP055445211 [X] 1,2,8-12 * abstract * * page 4, paragraph 1.3 * * Use of anti-PD-L1 in conjunction with DC-tumour Fusion Cells.; page 9, paragraph 1.11 - page 10, paragraph top * * Modification of DC-tumour FC with TLR activators. e.g. CpG oligodeoxynucleotide motifs; page 7, paragraph 2 - page 8, paragraph 1 * DOI: http://dx.doi.org/10.3390/ijms17060828 | [X] - ZITVOGEL LAURENCE ET AL, "Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes GRA<;:A RAPOSO 4 &", NATURE MEDICINE, vol. 4, no. 5, (19980501), pages 594 - 600, URL: https://www.nature.com/articles/nm0598-594, XP055789247 [X] 3,8,9,11,12 * abstract * * Discussion; page 597, column 1, paragraph 1 - page 599, column 1, paragraph 2 * |